Immunocore, a biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, viral infections and autoimmune disease, has appointed James Sandy as Chief Development Officer and Julian Hirst as Director of Corporate Finance. These new positions will be based in the firm’s headquarter in Oxford, UK.
Sandy will be responsible for leading the clinical development of Immunocore’s growing pipeline of proprietary immuno-oncology drugs known as ImmTACs (Immune Mobilising Monoclonal T Cell Receptors Against Cancer) and for the company’s strategic pharmaceutical partnerships that include combination trials. Hirst will be responsible for supporting Immunocore’s management team and board on corporate and investment activities.
“Sandy and Hirst will provide experienced leadership to our clinical and corporate development activities as we continue to execute our strategy and strive to remain as a private company,” stated CEO Eliot Forster.
Sandy has more than 25 years’ experience in the pharmaceutical and biotechnology industries, covering a range of development phases and therapeutic areas, including oncology. Most recently he was Chief Development Officer at Creabilis. Prior to this, he held various senior positions at Pfizer.Das letzte Mahl 2017 live streaming film online
Hirst joined Immunocore in early 2015 as a consultant and played a key role in the coordination of the company’s recent $320 million Series A financing. He brings more than 25 years’ experience at a senior level in the investment banking industry, having been Vice Chairman and Head of Corporate Finance at Panmure Gordon, Head of European Technology and a Managing Director at UBS, and Head of European Media at Morgan Stanley.
As it builds out its senior management team, Immunocore has also established a new US office in Conshohocken, Philadelphia, which will accommodate the firm’s US clinical development, medical and regulatory operations and provide an important base for Immunocore’s ongoing US activities. It is not disclosed if the firm plans to hire senior members for its US branch in the near future.
Founded in 2008 originally out of Oxford University and headquartered outside Oxford, with an office outside Philadelphia, US, Immunocore now has more than 185 staff.
In July, Immunocore announced the participation of Fidelity Management & Research Company in its US $320 million (£205 million) private financing round. Fidelity has participated in the $320 million investment syndicate that includes Woodford Investment Management, Malin Corporation, Eli Lilly and Company, RTW Investments, other unnamed investors and existing shareholders.